Protara Therapeutics Inc.(TARA) announced updated results from its Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002, the Company's investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) patients with carcinoma in situ, or CIS (Ta/T1), who are Bacillus Calmette-Gurin (BCG)-Unresponsive or BCG-Nave.
According to the company, TARA-002 has shown remarkable efficacy, achieving a 100% complete response rate at any time and a 67% 12-month landmark complete response rate in BCG-unresponsive patients. Additionally, it demonstrated a 76% complete response rate at any time and a 43% 12-month landmark complete response rate in BCG-naïve patients. The treatment also boasts a favorable safety and tolerability profile, with no reported Grade 3 or higher treatment-related adverse events.
The company continues to expect to present an interim update with results from about 25 six-month evaluable BCG-Unresponsive patients by the end of 2025.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.